ISSN: 1300-7777 E-ISSN: 1308-5263
Results of treatment of acute myeloid leukemia and myelodysplastic syndrome with etoposide, thioguanine, cytarabine (ETC) in elderly patients [Turk J Hematol]
Turk J Hematol. 2006; 23(4): 193-196

Results of treatment of acute myeloid leukemia and myelodysplastic syndrome with etoposide, thioguanine, cytarabine (ETC) in elderly patients

Ahmet Öztürk, Alev Akyol Erikci, Özkan Sayan
Department Of Hematology, Gata Haydarpasa, İstanbul, Turkey

Treatment in elderly patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains controversial, and results have been poor with most regimens. In order to study the efficacy of a new regimen in the treatment of these diseases in elderly patients assessed as not tolerating full-scale anthracycline-containing intensive chemotherapy, 14 patients over 60 years were enrolled in our study. The median age was 69 years, range 60-85 years. Eight patients had MDS (one transformed to AML) and six had AML. Anthracycline-lacking therapy (ETC) consisted of etoposide 120 mg/m² and thioguanine 100 mg/m² p.o. twice daily on days 1-5 and cytarabine (araC) 40 mg/m² s.c. on day 1. The preliminary results were as follows: 7 of the 14 patients (50%) achieved complete remission. The median survival was 10 months. Days spent at hospital were 28. Neutropenia was observed for 11 days and thrombocytopenia for 15 days. No severe infection was detected. Early death was observed in 2 (14%) of the patients. In conclusion, this novel treatment with a complete response of 50% appears to be a simple, safe, cost-effective form of therapy for elderly patients.

Keywords: Acute myeloid leukemia, myelodysplastic syndrome, elderly patients


Yaşlı akut myeloid lösemili ve myelodisplastik sendromlu hastalarda etoposid, thioguanin, sitarabin tedavisinin sonuçları

Ahmet Öztürk, Alev Akyol Erikci, Özkan Sayan
Department Of Hematology, Gata Haydarpasa, İstanbul

Akut myeloid lösemili (AML) ve myelodisplastik sendromlu (MDS) yaşlı hastaların nasıl tedavi edileceği halen tartışmalıdır ve pek çok rejimle elde edilen sonuçlar olumsuzdur. Tam doz antrasiklin içeren yoğun tedavileri tolere edemeyecek 60 yaş üzerindeki 14 vakayı tedavi rejiminin etkinliğini göstermek için çalışmamıza aldık. Ortalama yaş 69 idi ve 60 ile 85 arasında değişmekte idi. Sekiz hastada MDS (biri AML ye dönüştü), 6 tanesinde de AML vardı. Tedavi etoposid 120 mg/m² ve thioguanin 100 mg/m² p.o. günde iki kez 1-5.günler ve araC 40 mg/m² s.c. 1. günde verildi (ETC). Çalışmanın ilk sonuçlarında; on dört hastanın 7sinde (%50) tam yanıt elde edildi. Ortalama yaşam süresi 10 aydı. Hastanede geçirilen ortalama günler 28 gündü. Ortalama nötropeni süresi 11 gün iken trombositopeni süresi 15 gündü. Ciddi hiçbir enfeksiyon tespit edilmedi. Erken ölüm 2 (%14) hastada izlendi. Sonuç olarak bu yeni tedavi yaklaşımı yaşlı hastalarda %50’lik tam yanıt oranı ile basit güvenli ve ekonomik bir tedavi seçeneğidir.

Anahtar Kelimeler: Akut myeloid lösemi, myelodisplastik sendrom, yaşlı hastalar


Ahmet Öztürk, Alev Akyol Erikci, Özkan Sayan. Results of treatment of acute myeloid leukemia and myelodysplastic syndrome with etoposide, thioguanine, cytarabine (ETC) in elderly patients. Turk J Hematol. 2006; 23(4): 193-196

Corresponding Author: Alev Akyol Erikci, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686